Several small-molecule inhibitors have successfully disrupted the interaction between N-MYC and AURKA, leading to the destabilization and degradation of N-MYC and subsequently tumor regression in MYCN amplified cancers [46,47,48]. The gene discussed is MYCN; the disease is cancer.